Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.

Autor: Cardillo TM; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Zalath MB; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Arrojo R; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Sharkey RM; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Govindan SV; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Chang CH; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Goldenberg DM; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; Current address: Center for Molecular Medicine and Immunology, Mendham, NJ 07945, USA; E-mail, dmg.gscancer@att.net.; At the time the work was conducted, this author was Chairman and Chief Scientific Officer of Immunomedics, Inc., which he founded in 1982.

Publikováno v: Oncotarget [Oncotarget] 2024 Feb 22; Vol. 15, pp. 144-158. Date of Electronic Publication: 2024 Feb 22.

Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.

Autor: Touchefeu Y; Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, France. yann.touchefeu@chu-nantes.fr.; Institut des Maladies de l'Appareil Digestif, University Hospital, Nantes, France. yann.touchefeu@chu-nantes.fr., Bailly C; Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, France., Frampas E; Radiology department, University Hospital, Nantes, France., Eugène T; Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, France., Rousseau C; Université de Nantes, ICO Gauducheau, CNRS, Inserm, CRCINA, F-44000, Nantes, France., Bourgeois M; Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, France., Bossard C; Pathology Department, University Hospital, Nantes, France., Faivre-Chauvet A; Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, France., Rauscher A; Pharmacy Unit, ICO Cancer Center, Saint-Herblain, France., Masson D; Biology Department, University Hospital, Nantes, France., David A; Radiology department, University Hospital, Nantes, France., Cerato E; Délégation à la Recherche Clinique et à l'Innovation, University Hospital, Nantes, France., Carlier T; Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, France., Sharkey RM; Immunomedics, Inc., Morris Plains, NJ, USA., Goldenberg DM; Immunomedics, Inc., Morris Plains, NJ, USA.; IBC Pharmaceuticals, Inc., Morris Plains, NJ, USA., Barbet J; GIP Arronax, F-44800, Saint-Herblain, France., Kraeber-Bodere F; Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, France.; Université de Nantes, CHU Nantes, ICO Gauducheau, CNRS, Inserm, CRCINA, F-44000, Nantes, France., Bodet-Milin C; Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, France.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Mar; Vol. 48 (3), pp. 874-882. Date of Electronic Publication: 2020 Aug 21.

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

Autor: Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Messersmith WA; University of Colorado Cancer Center, Aurora, USA., Kio EA; Goshen Center for Cancer Care, Goshen, USA., Berlin JD; Vanderbilt-Ingram Cancer Center, Nashville, USA., Vahdat L; Weill Cornell Medicine, New York, USA., Masters GA; Helen F Graham Cancer Center and Research Institute, Newark, USA., Moroose R; Orlando Health UF Health Cancer Center, Orlando, USA., Santin AD; Yale University School of Medicine, New Haven, USA., Kalinsky K; Columbia University Irving Medical Center-Herbert Irving Comprehensive Cancer Center, New York, USA., Picozzi V; Virginia Mason Cancer Center, Seattle, USA., O'Shaughnessy J; Texas Oncology, Baylor University Medical Center, US Oncology, Dallas, USA., Gray JE; H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA., Komiya T; Parkview Cancer Institute, Fort Wayne, USA., Lang JM; University of Wisconsin Carbone Cancer Center, Madison, USA., Chang JC; Houston Methodist Cancer Center, Houston, USA., Starodub A; Riverside Peninsula Cancer Institute, Newport News, USA., Goldenberg DM; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA., Sharkey RM; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA., Maliakal P; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA., Hong Q; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA., Wegener WA; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA., Goswami T; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA., Ocean AJ; Weill Cornell Medicine, New York, USA. Electronic address: ajo9001@med.cornell.edu.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 746-756. Date of Electronic Publication: 2021 Mar 16.

Optimized method for fluorine-18 radiolabeling of Affibody molecules using RESCA.

Autor: Lechi, Francesco¹ (AUTHOR), Eriksson, Jonas^1,2 (AUTHOR), Odell, Luke R.¹ (AUTHOR), Wegrzyniak, Olivia¹ (AUTHOR), Löfblom, John³ (AUTHOR), Frejd, Fredrik Y.^4,5 (AUTHOR), Zhang, Bo¹ (AUTHOR), Eriksson, Olof¹ (AUTHOR) olof.eriksson@ilk.uu.se

Publikováno v: EJNMMI Radiopharmacy & Chemistry. 10/26/2024, Vol. 9 Issue 1, p1-15. 15p.

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.

Autor: Kalinsky K; Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center-Herbert Irving Comprehensive Cancer Center, New York, USA. Electronic address: kk2693@cumc.columbia.edu., Diamond JR; Department of Medicine, Medical Oncology, University of Colorado Cancer Center, Aurora, USA., Vahdat LT; Department of Medicine, Weill Cornell Medical College, New York, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Juric D; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., O'Shaughnessy J; Department of Medical Oncology, Texas Oncology, Baylor University Medical Center, US Oncology, Dallas, USA., Moroose RL; Department of Hematology/Oncology, Orlando Health UF Health Cancer Center, Orlando, USA., Mayer IA; Department of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, USA., Abramson VG; Department of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, USA., Goldenberg DM; Clinical Development, Immunomedics, Inc., Morris Plains, USA., Sharkey RM; Clinical Development, Immunomedics, Inc., Morris Plains, USA., Maliakal P; Clinical Development, Immunomedics, Inc., Morris Plains, USA., Hong Q; Clinical Development, Immunomedics, Inc., Morris Plains, USA., Goswami T; Clinical Development, Immunomedics, Inc., Morris Plains, USA., Wegener WA; Clinical Development, Immunomedics, Inc., Morris Plains, USA., Bardia A; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2020 Dec; Vol. 31 (12), pp. 1709-1718. Date of Electronic Publication: 2020 Sep 15.